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Saccharomyces cerevisiaeOne of the paradigms in cancer pathogenesis is the requirement of a cell to undergo transformation from respiration
to aerobic glycolysis – the Warburg effect – to become malignant. The demands of a rapidly proliferating cell for
carbon metabolites for the synthesis of biomass, energy and redox equivalents, are fundamentally different from
the requirements of a differentiated, quiescent cell, but it remains open whether this metabolic switch is a cause
or a consequence of malignant transformation. One of the major requirements is the synthesis of lipids for
membrane formation to allow for cell proliferation, cell cycle progression and cytokinesis. Enzymes involved in
lipid metabolism were indeed found to play a major role in cancer cell proliferation, and most of these enzymes
are conserved in the yeast, Saccharomyces cerevisiae. Most notably, cancer cell physiology and metabolic ﬂuxes
are very similar to those in the fermenting and rapidly proliferating yeast. Both types of cells display highly active
pathways for the synthesis of fatty acids and their incorporation into complex lipids, and imbalances in synthesis
or turnover of lipids affect growth and viability of both yeast and cancer cells. Thus, understanding lipidmetabolism
in S. cerevisiae during cell cycle progression and cell proliferationmay complement recent efforts to understand the
importance and fundamental regulatory mechanisms of these pathways in cancer.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
In their review “TheHallmarks of Cancer”, Hanahan andWeinberg [1]
deﬁned six alterations in cellular processes that are required to turn a
normal cell into a cancer cell: response to growth and antigrowth signals,
prevention of apoptosis and senescence, induction of angiogenesis,
and the ability to colonize other body parts. These milestones in cancer
development, however, are exclusively addressing regulatory and
signaling processes. In a recentupdate of theirwork, the authors expand-
ed their list of required modiﬁcations for cancer development by two
novel – emerging – hallmarks, namely defense against immune destruc-
tion andmodiﬁcations in energymetabolism [2]. The latter – energyme-
tabolism – is in fact a trait, which has been described in some detail
already in the twenties of the last century. Otto Warburg published his
observations that themetabolismof cancer cells is shifted from the oxida-
tion of glucose to carbon dioxide and respiration-driven ATP production
to fermentative reduction of pyruvate to lactate. Under these conditions,
ATP is mainly derived from cytosolic glycolysis, which, however, is a
much less efﬁcient pathway to generate energy compared tomitochon-
drial respiration [3]. Only a few years later, Herbert G. Crabtree showed
that mitochondrial respiration in neoplastic tissue is repressed at
physiological glucose concentrations [4]. Warburg concluded from his: +43 316 380 9854.
.
-ND license.seminal work that cancer cells develop due to defective mitochondrial
respiration, forcing the cell to shift to aerobic fermentation, even if
oxygen supply is not limiting [5]. Although it has been shown mean-
while that cancer cells are not necessarily compromised in respiratory
activity, the switch to high glucose uptake rates and fermentative me-
tabolism is still considered a property of almost all types of tumors
[6,7]. The reasons for this physiological switch remain a matter of
debate. Reduction of the metabolic ﬂux from pyruvate to lactate results
in sensitivity of cancer cells to hypoxic conditions and impaired growth
[8]. However, it is unclear whether aerobic glycolysis is a prerequisite
for a cell to become neoplastic or if this dramatic switch in metabolism
occurs concomitantly to, or after malignant transformation. It has also
been suggested that aerobic glycolysis that is accompanied by high
glucose uptake rates and acidiﬁcation of the extracellular environ-
ment, is a response to hypoxic conditions and may provide a growth
advantage. Similarly, aerobically fermenting yeasts, which convert
glucose to ethanol and acetic acid at high rates, prevent competing
microorganisms from growth, while being tolerant to high ethanol
concentrations and low pH themselves [9]. In addition, reduced mito-
chondrial activity might contribute to the ability of cancer cells to evade
apoptosis. Although aerobic glycolysis generates only 2 mol of ATP per
mol of glucose, the overall rate of ATP production might indeed be
higher in aerobic glycolysis than in mitochondrial respiration, due to
lower costs for enzymeproduction or higher activities of the fermenting
enzymes, compared to tricarboxylic acid (TCA) cycle and respiratory
chain enzymes and cofactors [10,11].
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By considering metabolic ﬂuxes it becomes obvious that a rapidly
proliferating cell not only relies on sufﬁcient supply of energy in the
form of nucleoside triphosphates, but also on a sufﬁcient ﬂux of
glucose- or amino acid-derived metabolites into biosynthetic pathways
to fuel the duplication of biomass during every cell cycle (Fig. 1). In
addition to the consumption of energy and carbon precursors, these bio-
synthetic activities require numerous anaplerotic reactions, especially in
the TCA cycle, and the maintenance of a redox balance for the major
redox cofactors, NAD+/NADHandNADP+/NADPH. Since the production
of biomass from glucose-derived metabolites is mainly a reductive pro-
cess that requires NADPH for the synthesis of amino acids and lipids,
pathways for reduction of NADP+ have to be activated and the cytosolic
NADH has to be rapidly re-oxidized to maintain high glycolytic rates.
In contrast, a differentiated non-proliferating cell has no or only minorFig. 1. Interconnections between central carbonmetabolism and lipid synthesis. Yeast and canc
of biomass. For lipid synthesis, themajor carbon precursor is acetyl-CoA, derived from the ATP:c
Essential cofactors in lipid synthesis are ATP and NADPH. In addition, the acyl chain acceptors in
yeast maintain high glycolytic rates for biomass formation and for ATP production by substrat
cytosolic reactions: in cancer cells, pyruvate is reduced to lactate. In yeast, reduction is preced
ethanol are excreted from the cell. Metabolites and cofactors required for lipid synthesis are
DHAP — dihydroxyacetone phosphate, GAld-3-P — glyceraldehyde-3-phosphate, 6-
1,3-bisphosphoglycerate, 2(3)-PG— 2(3)-phosphoglycerate.activity of anaplerotic biosynthetic pathways and can fully oxidize
glucose to obtain the maximum possible ATP yield. This demand for a
balanced supply of energy, redox equivalents and biomass precursors
at high rates may provide an explanation for the switch of cancer cells
to aerobic glycolysis, accompanied by high rates of glucose uptake and
catabolism.
In an attempt to simulate the growth behavior and physiology
of a cancer cell with constraint based ﬂux balance analysis (FBA),
Shlomi et al. showed that their metabolic model switched from
respiration to aerobic glycolysis at high speciﬁc growth rates
when a constraint for the enzyme solvent capacity of the cellular
milieu was introduced [12]. In this simulation, kinetic constants
of metabolic enzymes were introduced to allow for the computa-
tion of required enzyme concentrations at a given speciﬁc growth
rate. A shift from respiration with high ATP yield to low yield overﬂow
metabolism occurs when the enzyme concentrations and theirer cells rely on increased glucose uptake andhigh glycolytic activity to fuel the biosynthesis
itrate lyase reaction in humans and from the pyruvate decarboxylase shunt in S. cerevisiae.
phospholipid synthesis, G-3-P and DHAP, are products of glycolysis. Both cancer cells and
e-level phosphorylation. Most of the NADH derived from glycolysis is reoxidized through
ed by decarboxylation of pyruvate to acetaldehyde, and yields ethanol. Both lactate and
printed in red, red arrows indicate reactions known to be up-regulated in cancer cells.
P-GlcL — 6-phosphoglucono-δ-lactone, PEP — phosphoenolpyruvate, 1,3-PG —
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sults in a loss of carbon conversion efﬁciency [12]. Similar results are
obtained by FBA with metabolic models of Saccharomyces cerevisiae, al-
though in most of these simulations uptake of oxygen is used as a con-
straint to shift cells from respiration to fermentation [13], a behavior
that is known as the Crabtree effect in yeast.
S. cerevisiae is often considered an organism that is almost entire-
ly committed to fermentative metabolism. Thus, the physiology of a
yeast cell and a proliferating cancer cell is very similar with compa-
rable metabolic ﬂuxes in these two cell systems [14]. It has to be
noted, however, that the degree to which cancer cells are commited
to aerobic glycolysis can vary in a broad range, but not to the same ex-
tent as in yeast, where respiratory activity is rather low in the presence
of glucose. Aerobic glycolysis in yeast relies on high glucose concentra-
tions: when yeast is cultivated in continuous culture under steady state
conditions (chemostat) with glucose as the limiting nutrient, cells grad-
ually switch to respiration when the dilution rate (i.e. the rate of
nutrient supply) is reduced: at dilution rates of 0.1 h−1, i.e. at a
speciﬁc growth rate μ=0.1 h−1, metabolism of yeast is fully respi-
ratory. Indeed, aerobic glycolysis is absent in yeast cultures at glu-
cose concentrations in the range of physiological serum glucose
levels in humans (~1 g L−1), but is gradually induced when the
glucose concentration is increased above this value. Due to this be-
havior yeast is a good model to study changes on transcriptional or
posttranslational levels or in metabolic ﬂuxes that are associated
with the transition from respiration to fermentation [15–17]. The
Crabtree effect is genetically determined and reversible in yeast,
whereas the Warburg effect in cancer cells seems to be a conse-
quence of spontaneous mutations; it is noteworthy, however,
that development of cancer and mortality correlate with blood glu-
cose levels in many cases [18–22]. Hence, increased glucose levels
seem to be associated with the switch of neoplastic cells from res-
piration to aerobic glycolysis, as is also the case in yeast.
Irrespective of the as yet unknown molecular mechanisms that
lead to the reprogramming of central carbon metabolism, this
transformation apparently provides cancer cells with growth and/
or survival advantages that are necessary for their rapid prolifera-
tion and invasiveness. Since this metabolic switch has been recog-
nized as an indispensable feature of neoplastic tissue, genes
involved in metabolism have become promising targets for cancer
therapy; accordingly, the involvement of cellular metabolism in
the development and progression of cancer has gained increased
attention in recent years. Although mammalian cells are able to
take up all major biomass constituents – glucose, amino acids,
fatty acids, cholesterol – from the bloodstream, proliferation of
cancer cells seems – at least in part – to rely on the endogenous
synthesis of these components, as indicated by the metabolic
switch to fermentation.
The major metabolic ﬂuxes in a proliferating cell are dedicated to
the synthesis of proteins and lipids, whereas only minor ﬂuxes con-
tribute to the synthesis of other components of biomass, such as
nucleic acids. Hence, lipid metabolism has an essential function in
biomass generation, and is also a major determinant of the cellular
redox status. Furthermore, several steps in lipid synthesis have been
recognized as being crucial for rapidly growing cancer and also for
yeast cells, emphasizing again the metabolic similarities between
both types of cells. In the following, we will review in greater detail
glycerolipid synthesis and its interconnection with glycolytic ﬂuxes
and cellular redox balance, in both yeast and cancer cells.
3. Lipids in yeast and mammals: Functional conservation and
structural differences
The basic pathways for the synthesis of membrane glycerolipids are
identical in yeast andmammalian cells (Fig. 2), resulting in the same clas-
ses of phospholipids (PL), namelyphosphatidic acid, phosphatidylinositol,phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine,
phosphatidylglycerol, and cardiolipin. Excess fatty acids (FA) that are
derived from endogenous de novo synthesis, lipid turnover or nutrition-
al supply are stored as triacylglycerol (TAG) in cytosolic lipid droplets,
keeping the total amount of cellular phospholipids within a narrow
range. The regulatory mechanisms that control the amount of cellular
phospholipids upon varying supplies with FA remain unknown. Major
differences between yeast and mammalian lipids exist with respect
to their FA composition, which, in yeast, is rather simple, and
consists mainly of palmitic and stearic acid, and their monounsatu-
rated derivatives, palmitoleic and oleic acid, respectively [23,24]. In
addition to these major FA, polyunsaturated FAs with 18–24 carbon
atoms contribute considerably to the total FA pool in mammalian
cells, dependent on the type of tissue [25–29]. Yeast membranes
contain the inositol-containing sphingolipids, phosphorylceramide,
mannosylinositol phosphorylceramide and mannosyldiinositol
phosphorylceramide [30,31]. Mammalian sphingolipids are more
complex, with sphingomyelin being the major sphingolipid, in addi-
tion to various classes of saturated and unsaturated ceramides
[32,33]. Cholesterol and ergosterol are essential sterols of cellular
membranes in mammals and yeast, respectively. Besides inﬂuencing
ﬂuidity of membranes they are involved in correct localization and
tertiary structure of membrane proteins and in the formation of
local asymmetries in the membrane, such as lipid rafts, which are
sphingolipid- and sterol-rich microdomains of the plasma mem-
brane [34–40]. Yeast ergosterol and mammalian cholesterol, although
structurally similar, are functionally not completely identical [41–44].
Both types of sterols can be esteriﬁed with FAs and stored in a
biophysically inert form in lipid droplets, together with TAG. Both
yeast and mammalian cells store FA as TAG, which might function
as a reserve for the production of energy or as a supply of FA for
the synthesis of complex lipids, dependent on nutritional state and
growth conditions. Especially the regulatory interplay and metabolic
inter-conversion between storage lipid (i.e. TAG) and membrane lipid
(i.e. PL) have recently been recognized as an important determinant
of cellular growth and proliferation in yeast [13,45], whereas the
β-oxidation of fatty acids for generation of energy is repressed when
glucose is present as the carbon source. Furthermore, peroxisomes
are the exclusive site of FA breakdown in yeast, which is in contrast
to higher organisms where this pathway is active in both, peroxi-
somes and mitochondria. In mammals, FA released from TAG are
generally assumed to be destined for β-oxidation, although increas-
ing evidence accumulates that indicates additional roles for lipoly-
sis, including the release of metabolic signaling molecules [46]. A
role of lipolysis-derived FA in phospholipid synthesis or turnover
has not yet been described for mammalian cells.
4. Central carbon metabolism provides the building blocks
for membranes
All pathways for lipid syntheses share one common precursor,
acetyl-CoA, and are characterized by a high demand of reductive
power in the form of NADPH. For example, synthesis of one molecule
of palmitic acid requires 8 acetyl-CoA and 14 NADPH molecules:
8 acetyl−CoAþ 7 ATPþ 14 NADPH→
C16:0−CoAþ 7 CoASHþ 14 NADPþ þ 7 ADP
ð1Þ
According to this equation (for simpliﬁcation, equations are
not balanced for H+, H2O, and inorganic phosphate), synthesis
of one glycerophospholipid molecule with one C16 and one C18
FA consumes 17 acetyl-CoA and 30 NADPH molecules. Synthesis
of sphingolipids follows a similar stoichiometry. Sterols, although synthe-
sized in a completely different pathway, require comparable amounts of
acetyl-CoA and NADPH as the synthesis of glycerophospholipids. Substi-
tution of acetyl-CoA and NADPH in Eq. (1) with glucose as the carbon
Fig. 2. Metabolic pathways for the synthesis of glycerolipids. Due to their increased demand for membrane lipids, most cancers show a lipogenic phenotype. Most prominent are the
upregulation of acetyl-CoA carboxylase and fatty acid synthase. Additionally, increased remodeling of phosphatidylcholine is observed in many malignous tissues. Pathways for the synthesis
of CTP, the energy donor for phospholipid synthesis, of glycerol-3-phosphate, the FA acceptor in PA synthesis, of unsaturated FA and of phosphocholine are activated in some tumors. The
storage form of lipids, triacylglycerol, is also involved in the remodeling of membrane lipids in proliferating cells, as suggested by altered regulation of lipases in cancer tissues. Red arrows in-
dicate pathways that were found to play a role in cancer cells. CDP-Cho — CDP-phosphocholine, CDP-Etn— CDP-ethanolamine, Cho— choline, CL— cardiolipin, CTP— cytidine triphosphate,
DAG— diacylglycerol, Etn— ethanolamine, FFA— free fatty acids, DHAP— dihydroxyacetone phosphate, G3P— glycerol-3-phosphate, GP-Cho— glycerophosphocholine, PC— phosphatidyl-
choline, P-Cho— phosphocholine, PE— phosphatidylethanolamine, P-Etn— phosphoethanolamine, PI— phosphatidylinositol, PS— phosphatidylserine, UTP — uridine triphosphate.
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for NADPH results in the following equation:
21 glucoseþ 59 NADþ þ 34 ATPþ 3 CoASH→
3 C16:0−CoAþ 11 pyruvateþ 34 ADPþ 45 CO2 þ 59 NADH
ð2Þ
These equations illustrate that proliferating cells have a high
demand for carbon precursors and redox equivalents for mem-
brane biogenesis, which makes lipid synthesis one of the major
consumers of acetyl-CoA and NADPH in the cell, besides amino
acid synthesis. In comparison to these requirements, the con-
sumption of ATP in the pathways for biomass production is mod-
erate and can be met by low respiratory activity or – as in
Warburg positive cancers and in fermenting yeast – by substrate
level phosphorylation alone, followed by reduction of pyruvate to
lactate (ethanol in yeast) for regeneration of NAD+.Although proliferating cancer cells could satisfy their demand for
lipids by the uptake of lipoprotein, the major part of FAs seems to be
generated by de novo FA synthesis [47], corroborating the importance
of metabolic adaptation to anabolic processes in rapidly proliferating
cells.
Notably, acetyl-CoA in S. cerevisiae and mammalian cells is
generated by somewhat different pathways (Fig. 1). Crabtree
positive yeasts convert most of the pyruvate from glycolysis to
acetaldehyde, which is either reduced to ethanol for regeneration
of NAD+ or oxidized to acetate. Both ethanol and acetate can be
excreted into the medium. Most of the acetate, however, is acti-
vated to acetyl-CoA. During fermentation in the presence of high
glucose concentration, S. cerevisiae produces approximately 160
molecules of ethanol and only 7 molecules of acetyl-CoA per
100 molecules of glucose taken up from the medium [15], em-
phasizing the rather wasteful utilization of carbon source. Only
minor amounts of pyruvate are converted to mitochondrial
acetyl-CoA by pyruvate dehydrogenase, which is further metabo-
lized to 2-ketoglutarate for the synthesis of amino acids.
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pressed and not active at high glycolytic rates.
In mammalian cells, acetyl-CoA is derived from the reaction
citricacidþ ATPþ CoASH→oxaloaceticacidþ acetyl−CoAþ ADP ð3Þ
which is catalyzed by the cytosolic enzyme ATP:citrate lyase (ACL).
This reaction requires high activity of the ﬁrst steps of the TCA
cycle to generate citrate, which has to be translocated to the cytosol.
Interestingly, recent data suggest that most of the citrate in cancer
cells might be produced by carboxylation of α-ketoglutarate to
isocitrate, which is then further converted to citrate. This reductive
pathway to citrate requires high anaplerotic activity for
α-ketoglutarate and might therefore explain the preference of
many tumors for glutamine, which can be easily converted to
α-ketoglutarate [48–50].
The requirement for ACL in proliferating tissue is reﬂected in impaired
growth of tumors if the ACL gene is knocked down or if the enzyme activ-
ity is inhibited [51,52]. Furthermore, ACL expression and activity are
increased in lung cancer cells and increased activity is dependent on the
PI3P/Akt pathway [53]. Concomitantly, intracellular neutral lipid pools
are ﬁlled up when ACL expression is knocked down, which also attenu-
ates the growth rate of lung cancer cells [53]. Increased neutral lipid
accumulation as a response to inhibited de novo FA synthesis seemspar-
adoxical. However, S. cerevisiae behaves in a similar way when the
growth rate decreases: upon entry into quiescence, cells start to accu-
mulate TAG and steryl esters in lipid droplets. These lipid pools are
only rapidly mobilized when growth is re-initiated in the presence of
nutrients [54].
In addition to its role as a substrate for lipid and amino acid syn-
thesis, acetyl-CoA is an important regulatory metabolite in the cell,
e.g. in histone acetylation. Acetylation of metabolic enzymes has
only recently been recognized as a means to regulate ﬂuxes through
central carbon metabolic pathways [55–57]. For example, the M2 iso-
form of pyruvate kinase PKM2, which is the isoform most active in
malignant tissue, is acetylated at one of its lysine residues, K305 [58].
This modiﬁcation results in a reduction of PKM2 activity and protein
stability, which is thought to be responsible for attenuating the glyco-
lytic ﬂux and thereby making intermediate metabolites available for
biosynthetic reactions. Mutation of K305 to a non-acetylatable gluta-
mine residue increases cellular levels of NADPH, which indicates a
higher ﬂux through the pentose phosphate pathway (PPP). If the
level of PKM2 acetylation is a function of the cellular concentration
of acetyl-CoA, this regulation indeed leads to an increased supply of
NADPH for reductive biosynthetic pathways at high acetyl-CoA levels.
Whereas PKM1 and PKM2 are splice variants of one gene in mammals,
the yeast genome contains two genes encoding for pyruvate kinases,
namely CDC19 and PYK2. PYK2 is expressed only at low glucose levels
and, like mammalian PKM1, not subject to regulation by fructose-1,6-
bisphosphate. Under fermentative conditions, Cdc19 is the active pyru-
vate kinase that is regulated by fructose-1,6-bisphosphate and through
phosphorylation by protein kinase A (PKA). Down-regulation of CDC19
gene expression results in a redirection of carbon ﬂuxes into the TCA
cycle, indicating higher respiratory activity. Whether the yeast pyruvate
kinase Cdc19 is also acetylated as part of this regulatory loop has not
yet been shown [59–62].
Attenuation of glycolysis through PKM2 acetylation might result
in increased ﬂuxes through several pathways, namely serine and gly-
cine synthesis from 3-phosphoglycerate, glycerol-3-phosphate from
dihydroxyacetone phosphate for glycerolipid synthesis, and the pen-
tose phosphate pathway for reduction of NADP+ and for the synthe-
sis of ribonucleic acids. Flux balance analysis in yeast shows that
about 50% of the NADPH is consumed by glutamate dehydrogenase,
the major reaction for ammonia assimilation; the remainder is
distributed 60:40 between amino acid (AA) and lipid synthesis. Inrapidly proliferating mammalian cells, which are relying on import
of AA from the environment (at least the essential AA), lipid synthesis
is presumably the major consumer of NADPH. Evidence suggests that
glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting en-
zyme in the pentose phosphate pathway, which generates NADPH,
indeed plays a role in cancer. It was shown for several tumors that
over-expression or increased activity of G6PD induces malignancy
or is required for proliferation of cancer cells [63–68]. Increased activ-
ity or expression in cancer tissue has also been shown for the subse-
quent steps of the PPP [69,70]. The tumor suppressor p53 directly
binds to G6PD, preventing the enzyme from forming the active
homodimer; furthermore mutated forms of p53, such as found in tu-
mors, are unable to inhibit G6PD activity [64]. In yeast, G6PD is
encoded by the ZWF1 gene. Zwf1, like human G6PD, is negatively reg-
ulated by NADPH levels [71]. Interestingly, an additional inhibition of
yeast Zwf1 by palmitoyl-CoA has been reported [72], which indicates
a feedback regulation of NADPH production by the end product of
fatty acid synthesis, further supporting the assumption that the PPP
plays an important role in maintaining a high NADPH/NADP+ ratio
for lipid biosynthesis in proliferating cells. These aspects make yeast
a promising model for functional studies on the role of G6PD, since
human G6PD is able to complement the phenotype of a Zwf1 deﬁ-
cient yeast mutant [73].
5. Fatty acid synthesis: A major sink for acetyl-CoA and NADPH
Tumor cells are characterized by elevated FA synthesis. The ﬁrst and
committed step is the conversion of acetyl-CoA tomalonyl-CoA (Fig. 2),
catalyzed by acetyl-CoA carboxylase (ACC). Interferencewith ACC activ-
ity, either by use of inhibitors or by silencing gene expression, was
shown to be deleterious for several types of cancer cells [74–76]. Treat-
ment of prostate cancer cells with the ACC-speciﬁc inhibitor soraphen A
leads to growth arrest and, ultimately, cell death. [74]. Mammalian ACC
bears at least three phosphorylation sites for AMP activated kinase,
AMPK [77], which is one of themajor regulators of cellular homeostasis
in response to metabolic and energy status of the cell. AMPK phosphor-
ylation of ACC reduces its activity, resulting in reduced ﬂuxes of
acetyl-CoA to malonyl-CoA and, hence, attenuates lipogenesis under
conditions of low cellular energy load. Other targets of AMPK in lipid
metabolism are HMG-CoA reductase, the committed step in sterol syn-
thesis, and hormone sensitive lipase, HSL, which are both inhibited by
AMPK phosphorylation. There is little doubt about the connection be-
tween reduced activity of AMPK, or its upstream activator LKB1, and
cancer development, which has been demonstrated in countless studies
(see [78–80] for recent reviews). Thus, reduced activity of AMPKmay be
one of the major determinants for the metabolic reprogramming of a
cancer cell. Recent studies also suggest that AMPK might be linked
to the metabolic syndrome, type 2 diabetes or obesity and an in-
creased risk for cancer in patients with one of these disorders.
The AMPK homologue in yeast is Snf1; its name – Sucrose
Non-Fermenting – stems from the phenotype of mutants that are un-
able to express invertase, which is required for sucrose breakdown to
fructose and glucose [81–83]. Snf1 phosphorylates metabolic enzymes,
such as Acc1, as well as transcription factors and histones, and a deletion
of the SNF1 gene results in reduced growth rates and increased lipogene-
sis, due to the inability of themutant to phosphorylate and inactivateACC.
Interestingly, a SNF1 gene deletion also results in a reduced biomass yield
in a glucose-limited chemostat under respiratory conditions, but not in a
nitrogen-limited chemostat with fermentative metabolism. These results
suggest that yeast AMPK not only plays a role in carbon catabolite repres-
sion but also in the switch from respiration to aerobic glycolysis, or vice
versa [84].
In addition to its regulation at the level of gene expression and phos-
phorylation, ACC activity may also be regulated in a feedback loop
by the product of FA synthesis, acyl-CoA: ACC activity in mammals
[85–87] and presumably also in yeast [88], is inhibited by palmitoyl-
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shifted towards longer chain length (C18:0 and C18:1) in yeast snf1
mutants. The resulting lower levels of C16 fatty acids in cells with
impaired Snf1 function may result in an ever increased ﬂux from
acetyl-CoA to malonyl-CoA, thereby driving FA production due to the
observed changes in FA chain length distribution.
The second enzyme in de novo fatty acid synthesis, fatty acid
synthase (FASN), utilizes acetyl-CoA as a starter molecule and requires
one malonyl-CoA, one ATP and one NADPH molecule for each elonga-
tion step. FASN generates free fatty acid (in mammals) or acyl-CoA (in
yeast), typically 16 carbon atoms in length. Since its description as an
important player in development and growth of malignant tissue [89]
many studies have shown that FASN is one of the key metabolic
enzymes in uncontrolled proliferation of most cancer cells. Thus, FASN
has become one of the major targets in the search for anticancer thera-
pies, because its inhibition results in arrest of tumor growth and induc-
tion of apoptosis (for recent reviews, see [90–92]). FASN is also one of
the metabolic genes directly regulated by the oncogene HER2. In
breast cancer, overexpression of HER2 correlates with increased ex-
pression and activity of FASN [93], although FASN expression is not
directly controlled by HER2 but rather by sterol regulatory
element-binding protein (SREBP), the general transcriptional activa-
tor of lipogenic genes, via the PI3K/Akt pathway [94,95]. A recent
study also suggests an important role of the endoplasmic reticulum
lipid raft-associated protein 2, ERLIN2, in activation of SREBP. ERLIN2 is
overexpressed in breast tumors and seems to be required for activation
of SREBP1c by a mechanism that involves binding of INSIG1
(insulin-induced gene 1) by ERLIN2. In addition, ERLIN2 is involved in
the accumulation of triacylglycerol in cytosolic lipid droplets, indicating
a role of this protein in the distribution of fatty acids betweenmembrane
and storage lipids [96,97].
Whereas the product of fatty acid synthase in yeast is acyl-CoA,
mammalian FASN releases free fatty acid, which has to be activated to
acyl-CoA, a reaction catalyzed by acyl-CoA synthetase (ACS). Several
ACS isozymes have been shown to be upregulated in various types of
cancers and an inhibitor of ACS, Triacsin C,was shown to induce apopto-
sis in glioma cells [98–100]. Hence, not only the synthesis of FA per se,
but also the downstream pathways appear to be activated in cancer
cells.
6. Desaturation of fatty acids
Functionality of cellular membranes and activity of membrane bound
proteins are dependent on the FA composition of membrane lipids. To
establish and maintain the correct composition, C16 and C18 saturated
FA (SFA) derived from de novo synthesis are desaturated, yielding
mono- or polyunsaturated FA (UFA), and elongated to very long-chain
fatty acids, up to C26. Whereas the role of elongating enzymes in cancer
cells is only poorly studied [101], the desaturation of palmitic and stearic
acid to palmitoleic and oleic acid, respectively, is considered an important
factor in the synthesis of membrane lipids for mitogenic cells. For serum-
derived FAs, a positive correlation between increased oleic acid
levels or a decreased saturation index and breast cancer risk has
been suggested [102,103], although conﬂicting data exist [104,105].
Tumors with the lipogenic phenotype show a higher ratio of saturat-
ed to unsaturated FA, and treatment of cancer cells with the ACC in-
hibitor soraphen A results in increased levels of unsaturated FAs. The
authors argue that an increased saturation index serves as a protec-
tive mechanism due to a more rigid membrane architecture, and re-
duces oxidative stress that may result from oxidation of unsaturated
FA (UFA) [106].
Desaturation of FA relies on a complex reaction mechanism that
involves electron transfers between cytochrome b5, NADH, molecular
oxygen and the fatty acid substrate, catalyzed by the enzyme stearoyl-
CoA desaturase (SCD). Reports about transcriptional upregulation of
SCD1, the major desaturase in humans, in neoplastic tissue are scarce[107,108]. Nevertheless, the activity of the protein is indispensable for
cellular proliferation, and a reduction of its activity in tumors results
in growth inhibition [109,110]. Intriguingly, reduced activity of SCD1
seems to have an inhibitory effect on de novo fatty acid synthesis,
resulting in reduced levels of most lipid classes and increased apoptotic
cell death, suggesting a feedback regulatory mechanism to down-
regulate ACC and/or FASN. One possibility for such a mechanism would
be the inhibition of ACC by palmitoyl-CoA: reduced activity of the
desaturase results in an increase in palmitoyl-CoA, thereby increasing
the allosteric inhibition of ACC by palmitoyl-CoA. In contrast, increased
activity of SCD1 is expected to result in a depletion of saturated FA and,
hence, in increased ACC activity. In addition, it was found that AMPK-
catalyzed phosphorylation and inactivation of ACC are enhanced in cells
with reduced SCD1 activity due to increased phosphorylation/activation
of AMPK [110]. On the other hand, higher activity of the desaturase,
resulting in a shift of the FA composition to UFA, would also be detrimen-
tal for the cell. Over-expression of the yeast Δ9 desaturase Ole1 in cancer
cells has shown that these cells suffer from a dramatic increase in their
sensitivity to tumor necrosis factor, due to increased membrane ﬂuidity
[111]. These results corroborate the importance of an equilibrated supply
of saturated and unsaturated fatty acids for membrane lipids. For yeast,
we have recently shown that neutral lipid synthesis is involved in the
maintenance of this equilibrium. When mutants lacking the ability
to buffer excess FA into triacylgycerol are challenged with exoge-
nous oleic acid this results in a rapid increase of oleate-containing
membrane lipids and subsequent rapid loss of viability; saturated
FA, however, showed no such effect [23]. SFA may or may not be
irreversibly converted to UFA in the presence of oxygen to main-
tain the correct FA composition, and this process is strictly regulat-
ed by the activity of the Ole1 protein. Proliferating yeast cells
are readily capable of dealing with a signiﬁcant reduction of the
levels of UFA; in contrast, over-expression of the OLE1 gene rather
results in reduced growth rates and abnormal budding [112], indi-
cating that increased desaturase activity is in fact detrimental for
the cell.
Fatty acid desaturases are subject to tight control at the transcrip-
tional level from yeast to humans [113,114], on the level of mRNA
stability in yeast [115], and also with respect to protein stability
through the ubiquitin-proteasome-dependent ER-associated degra-
dation pathway [116,117]. Furthermore, evidence suggests that at
least the yeast enzyme is also regulated by the degree of saturation
of the membrane environment [118]. As a consequence of its puta-
tive role in the regulation of upstream enzymes involved in FA syn-
thesis (see above) and the importance of a balanced supply of
growing cells with SFA and UFA, SCD1 might become a promising
target in anti-cancer drug discovery.
7. Building cellular membranes: Phospholipid synthesis
Fatty acids are incorporated into glycerophospholipids by sequential
trans-esteriﬁcation of two acyl-CoA molecules to glycerol-3-phosphate
(G3P), yielding phosphatidic acid (PA). PA is either activated to
cytidyldiphosphate-diacylglycerol, the precursor for all phospho-
lipids, or dephosphorylated to diacylglycerol (DAG) by the enzyme
lipin (LPIN, Pah1 in yeast); DAG may be utilized for triacylglycerol
synthesis (see below), or channeled into the synthesis of phosphati-
dylethanolamine and phosphatidylcholine (PC) via the CDP-choline
(also termed ‘Kennedy’)-pathway (Fig. 2). Several of the key enzymes
in PL synthesis are up-regulated in cancer cells. The acceptor in the
acyl-transferase reactions, G3P, is generated by the reduction of dihy-
droxyacetone phosphate (DHAP), an intermediate of glycolysis. The
NADH-dependent glycerol-3-phosphate dehydrogenase (G3PD), which
catalyzes this step, was shown to be up-regulated in bladder cancer
[119]. Up-regulation of this pathwaymight serve a growing cell in several
ways: ﬁrst, the ﬂux to G3P provides the substrate for PL synthesis and
may perhaps be limiting for glycerophospholipid synthesis during
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glycolysis; third, G3PD is part of the glycerol phosphate shuttle: the com-
plete reaction cycle regenerates cytosolic NAD+ by transferring electrons
to mitochondrial FADH2 and, therefore, results in higher ATP levels, but
also in re-oxidation of G3P to DHAP. The full cycle is operating in mam-
mals, whereas in fermenting yeast it is incomplete due to glucose repres-
sionof themitochondrial G3Pdehydrogenase that catalyzes the oxidation
of G3P. Hence, the G3P shunt in yeast is only used for recycling of NAD+
and the synthesis of G3P for lipid synthesis and glycerol, which plays an
important role in osmoregulation. For the yeast Y. lipolytica it was
shown that overexpression of G3PD, deletion of the second enzyme of
the shuttle, GUT2, or a combination of both, had no effect on lipid
accumulation under standard growth conditions, suggesting that
the regeneration of NAD+ may be more important in this pathway
than the supply with G3P [120]. It is noteworthy that the acceptor
for the ﬁrst acyl-transferase reaction in S. cerevisiae can be both,
G3P and DHAP. Acylation of DHAP yields 1-acyl-DHAP, which has
to be reduced to LPA prior to the second acyl transfer, a reaction cat-
alyzed by the NADPH-dependent dehydrogenase Ayr1 (Fig. 1). The
regulatory mechanisms controlling the ﬂux distribution between
DHAP and G3P acylation are unknown. However, overexpression of
Ayr1 in yeast leads to growth arrest, demonstrating that the equilibrium
between these two pathways plays a crucial role in cellular proliferation
[121]. 1-acyl-DHAP reductase activity has also been detected in mam-
malian cells but the gene coding for this activity was not identiﬁed
[122].
Synthesis of all phospholipids, except for the synthesis of PA, re-
quires cytidine triphosphate as an energy donor, either for the conver-
sion of PA to CDP-DAG, or for the activation of phosphocholine (PCho)
and phosphoethanolamine to CDP-choline and CDP-ethanolamine,
respectively (Fig. 2). In yeast, the phosphorylation of DAG to PA by di-
glyceride kinase is also CTP-dependent, whereas this reaction is driven
by ATP hydrolysis in other organisms [123]. These observations indicate
an increased metabolic demand for CTP in proliferating cells. Indeed,
increased CTP synthase (CTPS) activity has been found in several cancers
[124–126], and negative effects of the CTPS inhibitor cyclopentenyl cyto-
sine on growth of malignant cell lines have been described [125,127].
CTPS apparently is mostly regulated at the post-translational level:
in addition to the well-known product inhibition, CTPS activity in
S. cerevisiae is regulated through phosphorylation at several sites on the
protein. The major yeast CTPS, Ura7, is a substrate of cAMP activated
protein kinase (PKA) and protein kinase C (PKC) at different serine
residues, in both cases with stimulating effects on enzyme activity
[128,129]. Both human CTP synthases were shown to functionally com-
plement yeast mutants lacking CTPS. CTPS1 is phosphorylated by PKA
and PKC, like the yeast Ura7 enzyme [130,131], and cyclopentenyl cyto-
sine also acts as an inhibitor of CTPS activity in yeast. Mutations of Ura7
and Ura8 that lead to a reduction of CTP product inhibition decrease
cyclopentenyl cytosine sensitivity of the enzymes; thesemutations con-
comitantly stimulate neutral lipid synthesis, and lead to a de-repression
of inositol biosynthesis and a shift of PC synthesis from the CDP-DAG
pathway to the Kennedy pathway [132].
8. Phospholipid remodeling pathways
The correlation of increased CTPS activity with a metabolic shift to
the CDP-choline pathway in yeast shows parallels to the observed
changes in PL metabolism of cancer cells. CDS1, the human CDP-DAG
synthase 1, was shown to be transcriptionally down-regulated in
hepatocellular carcinomas [133]. This decrease in CDS1 transcript
levels is an unexpected ﬁnding considering the general up-regulation
of pathways involved in membrane lipid synthesis, but it might be
compensated for by an increased ﬂux through the Kennedy pathway.
It has to be noted, however, that down-regulation of CDS1 has not yet
been described for other types of cancer. Furthermore, the Kennedy
pathway is also the major pathway for PC synthesis in non-cancerouscells [134], and the conclusion that cancer cells rely more strongly
on the Kennedy pathway for PC synthesis than non-cancerous cells
might be too simplistic. On the other hand, elevated levels of PCho are
observed in a wide variety of tumors [135], and choline kinase, which
catalyzes the conversion of choline to PCho is known to play a role in
many cancers [136]. Similarly, up-regulation of choline transporters
was observed in breast cancer cell lines [137,138]. Cki1, the choline
kinase in yeast, is phosphorylated by PKA and PKC, both stimulating
its activity [139,140]. PKA regulation is also assumed for human choline
kinase [141], however, no increased activity was so far reported for
other enzymes of the Kennedy pathway. In addition, ﬁndings that not
only PCho, but also glycerophosphocholine (GPCho) levels are increased
in some cancer tissues [135] point to the importance of an increased PC
turnover in these cells rather than at a shift from theCDP-DAG to theKen-
nedy pathway.
PChomay also be derived from PC catabolism through phospholipase
C, yielding diacylglycerol and PCho, or from recycling of GPCho, which is
the product of PC deacylation by phospholipase B. Both reactions contrib-
ute to the remodeling of phospholipids, a process that is required to
maintain the correct steady-state composition of PL species and their
acyl-chain distribution (Fig. 2). Phospholipase C-catalyzed turnover of
PC is required for the Ras oncogene mediated mitogenic signal cascade
that is important for cellular proliferation [142]. Hence, both the remod-
eling of PC to obtain an optimum FA composition and the production of
signalingmolecules, GPCho, PCho, andDAG,might be important for cellu-
lar growth. In S. cerevisiae, two enzymes are known to signiﬁcantly con-
tribute to PC turnover during exponential growth: the structurally and
functionally conserved neuropathy target esterase, Nte1, acts as a phos-
pholipase B and hydrolyzes PC derived from the Kennedy pathway. Nota-
bly, this enzyme is also involved in the transcriptional regulation of genes
involved in phospholipid metabolism [143–145]. Deletion of the NTE1
gene results in the down-regulation of choline uptake to compensate
for the reduced degradation of PC. In HeLa cells, NTE activity was
shown to be regulated in a cell cycle dependent manner, with highest
activity during G1 [146]. The second enzyme that degradesmetabolically
relevant amounts of PC is the phospholipid-dependent diacylglycerol
acyltransferase Lro1 (LCAT Related Open reading frame), which uses a
fatty acid from PC to acylate DAG to TAG. The human homolog of Lro1,
lecithin cholesterol acyltransferase (LCAT) catalyzes a similiar reaction.
However, the role of LCAT is rather the regulation of cholesterol ester
levels in serum than intracellular PC remodeling. Hence, a functional
homolog of Lro1 in humans remains to be identiﬁed. The byproduct of
Lro1, lyso-PC, is either further deacylated to FA and GPCho or reacylated
to PC by an acyl-CoA-dependent acyltransferase (Fig. 2). During exponen-
tial growth Lro1 is the major pathway for TAG synthesis in yeast,
underlining the importance of PL remodeling during cellular growth
[147]. Both Nte1 and Lro1 catalyze reactions that, either directly or indi-
rectly, promote synthesis of TAG and contribute to the adjustment of
the molecular species composition of membrane phospholipids. Notably,
several strainsmutated in genes involved in PCmetabolismwere recently
found to have additional defects in neutral lipid homeostasis [148]. These
results suggest that themetabolic crosstalk betweenmembrane and stor-
age lipids in proliferating cells is required for maintaining the optimum
membrane composition with regard to both FA and PL composition
(Fig. 3).
9. Neutral lipid homeostasis: How to deal with excess fatty acids
All eukaryotic cells store fat in intracellular lipid droplets (LD). De-
pendent on the organism and tissue, LDs are composed of TAG, steryl
esters and retinyl esters, with TAG being the predominant lipid class.
The classical view of the LD as an inert storage organelle for metabolic
energy in the form of TAG has changed during the last years and it is
now considered an organelle that is actively involved in lipid turn-
over, membrane formation and cellular proliferation. In humans, the
major site for lipid storage is the adipose tissue but neutral lipid
Fig. 3. Phospholipid remodeling in proliferating cells. The scheme shows the ﬂuxes of fatty acids in glycerolipid synthesis and the assumed involvement of storage lipids in the re-
modeling of membranes. FA are either incorporated into phospholipids for membrane biogenesis or into triacylglycerol for storage. Both membrane and storage lipids are subject to
turnover during growth, resulting in an acyl-CoA pool that is fed by de novo synthesis, lipolysis of TAG, and phospholipase B action on phospholipids. In yeast, FA from phospholipids
can also be directly incorporated into storage lipids by PC:diacylglycerol transferase activity and diacylglyerol derived from the ﬁrst step of TAG lipolysis may directly serve as a
substrate for synthesis of PE and PC in the Kennedy pathway or for the DAG kinase to generate phosphatidic acid (see main text for details).
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pocyte LDs are released and routed to β-oxidation when the body
needs more energy than is available from dietary intake. Conversely,
when the energy requirement of the cells is lower than the nutritional
supply, excess energy and carbon are channeled into one of the stor-
age depots, glycogen or fat. Notably, yeast cells proliferating in the
presence of high glucose concentrations accumulate only little TAG,
and only at the onset of starvation and entry into quiescence, the
remaining carbon source is converted into fat, resulting in high TAG
levels in stationary phase. When environmental conditions improve
such to support growth, TAG stores are rapidly degraded and the
fatty acids are channeled into phospholipid synthesis for fast progres-
sion through the ﬁrst cell division cycle. In contrast to higher organ-
isms, the pathway for β-oxidation of FA is strongly repressed during
growth of yeast on glucose [13,54].
The ﬁrst evidence that neutral lipid homeostasis might play an im-
portant role in cancer cells came from studies on the effects of
bexarotene, a synthetic ligand for retinoid X receptors (RXR), on mam-
mary tumors. RXR aremembers of the nuclear hormone receptor family,
with 9-cis retionic acid as the binding ligand. As homodimers or as
heterodimers with peroxisome proliferator-activated receptors
(PPARs) they regulate a plethora of processes in cellular develop-
ment and metabolism [149–151]. Synthetic RXR ligands, also termed
rexinoids, are under investigation as potent agents in therapy for
several cancers. Bexarotene induces the accumulation of triacylglycerol
in cytosolic lipid droplets and leads to an arrest of cell proliferation,
with PPARγ agonists acting synergistically to inhibit tumor growth
[152]. In cells treated with bexarotene mRNA expression of
acyl-CoA synthetase 1, stearoyl-CoA dehydrogenase and diac-
ylglycerol acyltransferase, key enzymes of FA and TAG metabolism,
are induced; another important factor in lipid homeostasis,
adipophilin, is elevated at the protein level upon treatment [152].Furthermore, the authors found a strong inverse correlation between
growth attenuation and neutral lipid accumulation in cancer cells,
which is also observed in yeast: in a genome-wide approach to iden-
tify yeast mutants with aberrant lipid droplet morphology, strains
with reduced growth rates were signiﬁcantly enriched in the group
of mutants with elevated lipid content [153].
Growth inhibition by rexinoids may operate by attenuating cell
cycle progression. Studies with the rexinoid LG100268 showed that ex-
pression of a key cell cycle regulator, cyclin D1, is strongly reduced in
the presence of the compound [154]. A growth arrest in cellswith active
lipid synthesismay trigger the cells to redirect theﬂux of FA frommem-
brane lipid synthesis to the synthesis of storage lipids, to avoid an accu-
mulation of excessmembranes. This hypothesis is supported by the fact
that PPARγ agonists act synergistically with rexinoids [152]. However,
the detailed mechanisms of rexinoid action remain to be elucidated.
Since the PPAR/RXR system can be reconstituted in yeast [155,156],
genome-wide drug screens in this model organism might help in this
endeavor.
Changes in lipid composition of tumor cells during apoptopic cell
death can be seen in this context. Several studies suggest that initia-
tion of apoptosis in cancer cells is accompanied by a remodeling of
glycerolipids, resulting in a drop of PC levels and an increase in
TAG [157,158]. As in the studies targeting RXR/PPARs, accumulation
of storage lipids is the consequence of attenuated growth. It is tempting
to speculate whether an increase of TAG synthesis might result in insuf-
ﬁcient membrane synthesis and therefore, in a reversal of cause and
effect, in growth arrest in proliferating cells. For baker's yeast it has
already been shown that an increase in activity of Lro1 results in re-
duced PC levels and increased TAG content, but an impact on cellular
proliferation has not been investigated in that study [159].
Storage of excess fatty acids into TAGor steryl esters is not an essential
process in yeast under normal growth conditions, as shown with a
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lenging this mutant with exogenous fatty acids results in proliferation
of intracellular membranes and cell death [23,160]. Hence, the inability
to detoxify excess FA by storage into LD can become detrimental for a
cell and interventions in the pathways for neutral lipid synthesis might
be a means to target proliferation of cancers with a lipogenic phenotype.
The assumption that lipid storage might be an important pathway in
some types of cancer is supported by evidence for upregulation of
ERLIN2 (see Section 5) in breast cancer and its involvement in lipid
droplet formation [97].
10. Neutral lipid mobilization: A role for TAG lipases in cell
proliferation?
When cells need the fatty acids stored in TAG for the production of
energy or for the incorporation into membrane lipids, lipases are acti-
vated to hydrolyze the ester bonds and release free FA. One of the four
TAG lipases in yeast, Tgl4, is activated by phosphorylation by cyclin-
dependent kinase 1, CDK1, a highly conserved key regulator of cell
cycle progression in yeast and mammalian cells. These ﬁndings link
TAG breakdown and the released metabolites directly to the control of
cell cycle events [45]. Lipolysis-derived DAG can be phosphorylated by
diglyceride kinase to PA and further processed tomembrane lipids during
the TAG mobilization phase [161], conﬁrming that TAG in fermenting
yeast is rather a storage pool for the rapid synthesis of membrane lipids
than a reserve for energy production through β-oxidation [13]. In addi-
tion, some evidence suggests that TAG-derived DAG may also be
channeled directly into the Kennedy pathway for phospholipid syn-
thesis. It might be speculated that FA are stored as TAG during phases
of reduced cell growth to support rapid membrane lipid synthesis at
later points of the cell division cycle, by utilizing TAG-derived FA or
DAG, in addition to de novo synthesis. Such a periodic accumulation
and degradation of neutral lipid would enable the cell to ﬁnish a cell
cycle, even if deprived of nutrients due to changing environmental
conditions once the cell is committed to enter a new round of cell di-
vision. The assumption that both TAG synthesis and lipolysis are si-
multaneously active processes in proliferating cells is supported by
the observation that lipase-deﬁcient yeast mutants accumulate
more TAG than WT cells at any given time point, without signiﬁcant
impact on cell size or growth rate. Hence, FA synthesis is stimulated
in these mutants, suggesting a role of lipases or the products of lipol-
ysis in control of FA synthesis. Overall, the reactions for de novo syn-
thesis and degradation of glycerolipids may result in a constant
exchange of FA between phospholipids and TAG to maintain the cor-
rect FA and PL composition of membranes in proliferating cells
(Fig. 3).
It remains to be shownwhether these events also occur in mamma-
lian cells, in particular in proliferating cancer cells. The functionally
conserved ortholog of Tgl4 in mammals, adipose triglyceride lipase
(ATGL), is also regulated by phosphorylation [162]. Regulation of lipol-
ysis by a cell cycle-dependent kinase in humans has not been dem-
onstrated yet, but there is clear evidence that lipolytic activity is
controlled by AMPK. Phosphorylation of ATGL by AMPK results in
increased enzymatic activity in adipocytes. On the other hand, phos-
phorylation of hormone-sensitive lipase HSL, the second enzyme in
the lipolytic cascade, through AMPK seems to result in inhibition of
its translocation to the lipid droplet and impaired lipolysis. Treat-
ment of cells with activators of AMPK, such as AICAR, results in in-
creased activity of ATGL and in repression of HSL [163–165].
AMPK-mediated stimulation of ATGL and inhibition of HSL would re-
sult in a halt of lipolysis after the inital step and in the need for an al-
ternative pathway to avoid accumulation of diacylglycerol, for
example the conversion of DAG to PC in the Kennedy pathway. How-
ever, regulation by AMPK is only one of several mechanisms that
control activity of ATGL and HSL. Furthermore, in non-adipose tissue
other TAG lipases besides ATGL might contribute considerably to TAGlipolysis. Therefore, the changes in lipolytic activity in cancer might de-
pend on several factors, including transcriptional regulation as well as
control of metabolic activity through PKA, AMPK, and cell cycle depen-
dent kinases. For AMPK, it might be expected that defects in the LKB1/
AMPK pathway, as observed in many cancers, affect this regulatory
network and result in altered TAG metabolism, but such a con-
nection has not been investigated yet. Notably, also expression of
monoacylglycerol lipase, which catalyzes the ﬁnal step in the lipolytic
cascade, is increased in colorectal cancer and evidence suggests that
its activity is required for rapid cell proliferation, since a gene knock-
down resulted in reduced tumor growth and elevated apoptotic cell
death [166].
ATGL needs the coactivator Comparative Gene Identiﬁcation-58,
CGI-58, for maximum activity [167]. CGI-58 was shown to possess
acyltransferase activity, required for the acylation of lysophosphatidic
acid to PA [168]. Interestingly, such an acyltransferase activity has also
been shown for the yeast TAG lipases Tgl3 and Tgl5. Deletion of TGL3
or TGL5 resulted in reduced PL levels and overexpression in an
increase of PL [169], again suggesting a direct involvement of storage
lipid pools in remodeling of membranes during growth (Fig. 3). In
mammals, TAG lipolysis is generally regarded as a means to generate
energy by β-oxidation of the released FA. Whether these FA can
also be used for lipid remodeling in proliferating cells remains to be
shown but the activity of CGI-58 as an acyltransferase suggests such a
pathway.
Lipolysis of fats seems to play a role not only in intracellular lipid
homeostasis of proliferating cells. Cachexia, the detrimental degra-
dation and loss of fat and muscle tissue that is associated with mul-
tiple types of cancer, is clearly linked to alterations in neutral lipid
turnover [170]. ATGL−/− ko mice are resistant to cachexia and simi-
lar results were obtained, althoughwith less signiﬁcance, for HSL−/−
mice. Moreover, the size of tumors in lipase mutant models was re-
duced in comparison to wild typemice, indicating a role of TAG lipol-
ysis not only in cachexia, but also in the development of the tumor
itself. In this study, TAG lipase activity in white adipose tissue of
cachexic patients was signiﬁcantly higher than in control groups
[170].11. Conclusion
Recent ﬁndings provide ample evidence that lipid metabolism plays
an important role in the development and growth of neoplastic tissue.
Alterations in the pathways for synthesis of fatty acids and their incor-
poration into phospholipids or storage into TAG are reported for a
large number of tumors. To identify potential targets for cancer therapy,
however, amore detailed understanding of the regulatory network that
controls lipid homeostasis is required.
In the past, work with yeast has provided a great deal of mecha-
nistic insight into fundamental cellular processes that are also rele-
vant for mammalian cells, such as TOR signaling, organelle
biogenesis, the secretory pathway, and cell cycle progression. Now,
is yeast as a single celled organism, also a suitable model to under-
stand cancer development? There is clear evidence that yeast that
typically grows in colonies, also bears properties of multicellular
complexity, illustrated by features such as the conserved mechanism
of programmed cell death [171] and physiological differences within
a colony [172]. Most notably, the metabolic reprogramming in can-
cer cells is similar to the physiology of fermenting yeast cells, and
the high level of pathway conservation in lipid metabolism offers
great potential for further mechanistic exploration. The convenience
of yeast regarding its genetic manipulation and growth conditions,
availability of large mutant collections and high-content screens as
well as drug susceptibility and detailed knowledge about physiology
and metabolism make this eukaryote an excellent experimental
model for such studies.
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